A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

NCT07406542 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic Breast Cancer

Interventions

DRUG: SYS6010
DRUG: Investigator's Choice of Chemotherapy (eribulin, capecitabine, gemcitabine, or vinorelbine)

Sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd.